⚠️FOR RESEARCH PURPOSES ONLY
ResearchPeptide

SS-31

Published Research

PubMed-indexed studies for SS-31

Research

Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.

Journal of neuroinflammation 2019
View on PubMed →
Research

SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2025
View on PubMed →
Research

Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction.

Mitochondrion 2024
View on PubMed →
Research

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.

International journal of molecular sciences 2025
View on PubMed →
Research

Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins.

GeroScience 2021
View on PubMed →
Research

Mitochondria-targeting peptide SS-31 attenuates ferroptosis via inhibition of the p38 MAPK signaling pathway in the hippocampus of epileptic rats.

Brain research 2024
View on PubMed →
⚠️ For laboratory research only. Not for human use.